石蕴琦,李占全

• 1:辽宁省人民医院心血管内科

摘要(Abstract)：

<正>肥厚型心肌病(hypertrophic cardiomyopathy,HCM)是常见的遗传性疾病,发病率约为0.2%,其中梗阻性肥厚型心肌病(hypertrophic obstructive cardiomyopathy,HOCM)约占HCM的25.0%,从婴儿到老年整个生命进程中均可发病。20世纪90年代HCM的年死亡率为1.5%,目前降至

关键词(KeyWords)： 梗阻性肥厚型心肌病;经皮室间隔心肌化学消融术;心肌切除术

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 石蕴琦,李占全

参考文献(References)：

• [1]Maron BJ,Ommen SR,Semsarian C,et al.Hypertrophic cardiomyopathy:present and future,with translation into contemporary cardiovascular medicine.J Am Coll Cardiol,2014,64:83-99.
• [2]Gersh BJ,Maron BJ,Bonow RO,et al.2011ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Thorac Cardiovasc Surg,2011,142:e153-203.
• [3]Cleland WP.The surgical management of obstructive cardiomyopathy.J Cardiovasc Surg(Torino),1963,45:489-491.
• [4]Ommen SR,Maron BJ,Olivotto I,et al.Long-term effects of surgical septalmyectomy on survival in patients with obstructive hypertrophic cardiomyopathy.J Am Coll Cardiol,2005,46:470-476.
• [5]Smedira NG,Lytle BW,Lever HM,et al.Current effectiveness and risks of isolated septalmyectomy for hypertrophic obstructive cardiomyopathy.Ann Thorac Surg,2008,85:127-133.
• [6]Maron BJ,Mc Kenna WJ,Danielson GK,et al.American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy.A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.J Am Coll Cardiol,2003,42:1687-1713.
• [7]Maron BJ.Hypertrophic cardiomyopathy:a systematic review.JAMA,2002,287:1308-1320.
• [8]Sigwart U.Non-surgical myocardial reduction for hyperropic obstructive cardiomyopathy.Lancet,1995,346:211-214.
• [9]Seggewiss H,Faber L,Gleichmann U.Percutaneous transluminalseptal ablation in hypertrophic obstructive cardiomyopathy.Thorac Cardiovasc Surg,1999,47:94-100.
• [10]Seggewiss H,Rigopoulos A,Welge D,et al.Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.Clin Res Cardiol,2007,96:851-855.
• [11]Alam M,Dokainish H,Lakkis N.Alcohol septal ablation for hypertrophic obstructive cardiomyopathy:a systematic review of published studies.J Interven Cardiol,2006,19:319-327.
• [12]Lyne JC,Kilpatrick T,Duncan A,et al.Longterm follow-up of the first patients to undergo trans catheter alcohol septal ablation.Cardiology,2010,116:168-173.
• [13]中华医学会心血管病学分会,中华心血管病杂志编辑委员会,室间隔心肌消融术治疗专题组.肥厚型梗阻性心肌病室间隔心肌消融术的中国专家共识.中华心血管病杂志,2011,39:886-892.
• [14]Perry ME,Aris A,Michael AB,et al.2014ESC guidelines on the diagnosis and management of hypertrophic cardiomyopathy.Kardiol Pol,2014,72:1054-126.
• [15]Alam M,Dokainish H,Lakkis NM.Hypertrophic obstructive cardiomyopathy alcoholseptal ablation vs.myectomy:a metaanalysis.Eur Heart J,2009,30:1080-1087.
• [16]Agarwal S,Tuzcu EM,Desai MY,et al.Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy.J Am Coll Cardiol,2010,55:823-834.
• [17]Leonardi RA,Kransdorf EP,Simel DL,et al.Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy:comparative rates of overall mortality and sudden cardiac death after treatment.Circ Cardiovasc Interv,2010,3:97-104.
• [18]Valeti US,Nishimura RA,Holmes DR,et al.Comparison of surgical septalmyectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.J Am Coll Cardiol,2007,49:350-357.